OVID Stock — Ovid Therapeutics Inc

Ovid Therapeutics Inc (OVID)

Updated October 16, 2026.

OVID is a Stock. Total return is -82.4% over the past 9.4 years, 351.5 points behind SPY at 269.1%.

Ovid Therapeutics is a biopharmaceutical company developing small molecule medicines for brain disorders, particularly epilepsies and seizure-related neurological conditions. The company's pipeline includes OV329, a GABA-AT inhibitor in Phase 1 clinical trials for drug-resistant epilepsies, and OV4071, a potassium-chloride cotransporter 2 activator in Phase 1 trials for psychosis associated with Parkinson's disease, Lewy body dementia, and acute schizophrenia. As an early-stage drug developer with collaboration agreements including AstraZeneca and H. Lundbeck, the company does not currently distribute income and is suited to investors with a higher risk tolerance who are focused on potential clinical and commercial development outcomes rather than current yield.

OVID performance versus SPY

Price and return data through 2026-10-16.

Total return is -82.4% over the past 9.4 years, 351.5 points behind SPY at 269.1%. Over the past year its total return — price change plus distributions reinvested — is 36.9%. Its deepest 1-year drawdown was 27.4%.

OVID key facts

Asset type

Stock

Asset class

Equity

Distribution frequency

None

Last close

$2.15 (as of 2026-10-16)

Market cap

$419,890,393

Average volume

1325038.0

Beta

0.23

Payout ratio

0.0%

Forward P/E

1.7918

EPS

$-0.22

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OVID risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 27.4%.

Who may consider OVID — and who may not

It is a weaker fit for investors who need monthly cash flow (OVID does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on OVID

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions